ClinicalTrials.gg
RecruitingNCT07369076Updated Sep 17, 2026

A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

A Phase 1/2 interventional study of NB-4746 High dose and NB-4746 Low dose in Amyotrophic Lateral Sclerosis (ALS), sponsored by Nura Bio. Recruiting at 12 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Nura Bio · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia — 8 open to participants now, 13 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Australia.

Planned enrollment
20th of 44
80 · median 63
Started
2026
with 2 others
Phase 1/2
3 of 44
2 open now
Primary completion
2027-04
later than 7 of 12 live
Registered
43rd of 44
by date

Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, this one is the 20th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 7 of the 12 other live ones, and was the 43rd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

8 of the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis.

The questions this trial aims to answer in comparing NB-4746 to placebo are:

  • What adverse events associated with taking NB-4746 are reported during this trial? (An adverse event is any sign or symptom that participants have during a trial. Adverse events may or may not be caused by treatments in the trial.)
  • How does NB-4746 move into, through, and out of the body of the participants?
  • What is the change in the level of neurofilament light (NfL) in the participants' blood? (NfL is a marker used to measure the extent of damage to the nerve cells.)

This trial has 2 parts. The trial doctors will start Part A before starting Part B of the trial. Participants have an option to enter the open label extension after completing Part A or Part B.

Part A: Participants will be randomly placed into 1 of the 3 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 capsules at a low dose to take by mouth twice daily for 1 month. Group 2: Participants will receive NB-4746 capsules at a high dose to take by mouth twice daily for 1 month. Group 3: Participants will receive placebo capsules to take twice daily for approximately 1 month.

Part B: Participants will be randomly placed into 1 of the 2 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 capsules at a dose determined by Part A to take by mouth twice daily for 12 weeks. Group 2: Participants will receive placebo capsules to take twice daily for approximately 12 weeks.

None of the participants, trial doctors, or trial staff will know which treatment the participants will receive during Part A or B. Some trials are done this way because knowing what treatment the participants receive can affect the results of the trial. Doing a trial this way helps to make sure that the results are looked at with fairness across all treatments.

Open-Label Extension: Upon the completion of Part A or Part B, the doctor will verify the participant's willingness to continue receiving study treatment. This open label extension continues until each participant completes up to 1 year of treatment. The trial doctors will check participants' ALS and general health throughout the trial.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis
  • ALS
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- ALS Criteria for Phase 1b:

  1. Participants in Phase 1b must have:

    1. Diagnosis of ALS per Gold Coast Criteria; and
    2. Symptom onset ≤48 months prior to randomization on Day 1. Date of first ALS symptom (any ALS symptom) onset is defined as the onset of weakness in the limbs, bulbar region, or trunk. Weakness in the bulbar region includes dysarthria and dysphagia.

      • ALS Criteria for Phase 2:
  2. Participants in Phase 2 must have:

    1. Diagnosis of ALS per Gold Coast Criteria; and
    2. Symptom onset ≤24 months prior to randomization on Day 1. Date of first ALS symptom (any ALS symptom) onset is defined as the onset of weakness in the limbs, bulbar region, or trunk. Weakness in the bulbar region includes dysarthria and dysphagia.

      • Additional Inclusion Criteria (All Participants):
  3. Male or female participants aged ≥18 years and ≤80 years at the time of signing .
  4. Participants must demonstrate functional oral intake and be independent of enteral nutritional support (e.g., PEG, G-tube) at the time of screening per Principal Investigator's judgement.
  5. Slow vital capacity (SVC) ≥60% of predicted at Screening.
  6. If taking riluzole, participant must be on a stable dose for ≥60 days prior to Screening lab blood draw.
  7. If taking edaravone, participant must have completed at least 1 cycle of edaravone prior to screening labs.
  8. Willing to adhere to requirements during the study period as described in Appendix 1.
  9. Capable of giving signed informed consent, as described in Section 13.2.2, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Presence of tracheostomy or permanent assisted ventilation; defined as > 22 hours daily of mechanical ventilation for more than 1 week (7 days).
  2. History or presence of uncontrolled medical conditions (other than ALS) that include cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs; or interfering with the interpretation of data as determined by the Investigator.
  3. Lifetime history of cancer except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years. Fully resected basal cell carcinoma and squamous cell carcinoma with no evidence of recurrence for 1 year are permitted.
  4. Female participants who have a positive serum pregnancy test at Screening, positive urine pregnancy test on Day 1, or who are breastfeeding on Day 1.
  5. Has a spinal deformity or other condition that may prevent the performance of a lumbar puncture.
  6. (INR) >1.4, count \<50,000/μL, or use of warfarin, heparin, or direct oral anticoagulants.
  7. History of Class III/IV heart failure (per [NYHA]).
  8. Inability to swallow or tolerate oral medications at Screening.
  9. Current participation in any other drug study or receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) before Screening.
  10. Known sensitivity to the NB-4746 study drug or any of the formulation components.
  11. Has received NB-4746 at any time prior to initial Screening.
  12. Any other reason that, in the opinion of the Investigator, would confound the conduct of this study or the interpretation of the results or that could compromise the participant's safety.
  13. Currently taking or planning to receive tofersen for the treatment of ALS.
  14. If a participant does not transition to the OLE in ≤30 days following completion of the main study, the participant will need to be rescreened for laboratory criteria and /pregnancy criteria.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Phase 1b - NB-4746, High dose

    Participants will receive two NB-4746 capsules (high dose), BID

    Drug: NB-4746 High dose

  • Experimental
    Phase 1b - NB-4746, Low dose

    Participants will receive two NB-4746 capsules (low dose), BID

    Drug: NB-4746 Low dose

  • Placebo comparator
    Ph 1b - Placebo

    Participants will receive two capsules of placebo per dose, BID.

    Drug: Placebo

  • Experimental
    Ph 2 - Active

    Participants will receive two capsules of NB-4746 (dose selected after review of Ph 1b data), BID

    Drug: NB-4746 (Dose TBD)

  • Placebo comparator
    Ph 2 - Placebo

    Participants will receive two capsules of placebo, BID

    Drug: Placebo

Interventions

  • DrugNB-4746 High dose

    NB-4746 will be administered twice daily in 2 capsules (high dose)

  • DrugNB-4746 Low dose

    NB-4746 will be administered twice daily in 2 capsules (low dose)

  • DrugPlacebo

    Two capsules of placebo will be administered twice daily.

  • DrugNB-4746 (Dose TBD)

    Two capsules of NB-4746 will be administered twice daily (dose will be defined after Ph 1b data is reviewed).

06

What researchers measure

Primary outcomes

  1. Ph 1b - Number of TEAEs and SAEs

    Number of treatment emergent adverse events (TEAEs) and number of serious adverse events (SAEs). This will be assessed in the Ph 1b part of the study.

    Time frame: From enrollment to 28 days

  2. Evaluate safety and tolerability of NB-4746 in adult participants with ALS.

    Incidence of treatment emergent adverse events (TEAEs) and abnormalities in vital signs, clinical laboratory assessments, and electrocardiograms (ECGs). This will be assessed in the Ph 2 part of the study

    Time frame: From enrollment to Week 12

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 27, 2026
StartActual
Mar 4, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Feb 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07369076
Lead sponsor
Nura Bio
Responsible party
Sponsor
First posted
Jan 27, 2026
Start date
Mar 4, 2026
Primary completion
Apr 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Lahar Mehta, MD
Contact
lmehta@nurabio.com
801-918-7637

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion